Memantine
FDA Approved
Description
Memantine is an NMDA receptor antagonist used to treat moderate to severe dementia and cognitive impairment. It provides neuroprotection and symptomatic benefit in organic brain syndromes and cognitive disorders. The drug is generally well-tolerated with a favorable safety profile.
Indications & Therapeutic Use
Alzheimer's disease, vascular dementia, organic brain syndrome, cognitive impairment
Linked Diseases:
organic brain syndrome
F06.9D019965
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Memantine
| Generic Name | Memantine |
| Brands | 1 brand available |
| Active Ingredient | Memantine hydrochloride |
| Drug Class | Alzheimer's disease |
| Manufacturer | Allergan |
| Dosage Forms | Oral tablet, 5mg, 10mg; oral solution 2mg/mL; extended-release capsule 7mg, 14mg, 21mg, 28mg |
| Medical Code | N06DX01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00322153 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes